Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus PD-1.

Trial Details

NCT ID
NCT05738694
Phase
PHASE3
Sponsor
ZHOU FANGJIAN
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Axitinib plus Toripalimab
  • nephrectomy
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Beijing, China|39.9075,116.39723
  • Guangzhou, China|23.11667,113.25
  • Hefei, China|31.86389,117.28083
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily agree to participate in this study and sign the informed consent form;
  • Males or females between 18 years old and 80 years old;
  • Diagnosed as clear cell carcinoma or renal cell carcinoma predominantly composed of clear cell carcinoma through histopathological examination
  • CT or MRI clinical staging is T2G4 or T2 with sarcomatoid differentiation, T3-4, N1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →